SE0200475D0 - Oral farmaceutisk beredning - Google Patents

Oral farmaceutisk beredning

Info

Publication number
SE0200475D0
SE0200475D0 SE0200475A SE0200475A SE0200475D0 SE 0200475 D0 SE0200475 D0 SE 0200475D0 SE 0200475 A SE0200475 A SE 0200475A SE 0200475 A SE0200475 A SE 0200475A SE 0200475 D0 SE0200475 D0 SE 0200475D0
Authority
SE
Sweden
Prior art keywords
suppository
tablet
composition
food supplement
polar lipids
Prior art date
Application number
SE0200475A
Other languages
English (en)
Swedish (sv)
Inventor
Bengt Hersloef
Per Tingvall
Original Assignee
Ltp Lipid Technologies Provide
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltp Lipid Technologies Provide filed Critical Ltp Lipid Technologies Provide
Priority to SE0200475A priority Critical patent/SE0200475D0/xx
Publication of SE0200475D0 publication Critical patent/SE0200475D0/xx
Priority to DE60327511T priority patent/DE60327511D1/de
Priority to JP2003567447A priority patent/JP2005520816A/ja
Priority to PCT/SE2003/000251 priority patent/WO2003068267A1/en
Priority to AT03703650T priority patent/ATE430585T1/de
Priority to PT03703650T priority patent/PT1474174E/pt
Priority to AU2003206355A priority patent/AU2003206355B2/en
Priority to EP03703650A priority patent/EP1474174B1/de
Priority to CNA038040131A priority patent/CN101060862A/zh
Priority to MXPA04007946A priority patent/MXPA04007946A/es
Priority to KR10-2004-7012595A priority patent/KR20040089633A/ko
Priority to NZ534812A priority patent/NZ534812A/en
Priority to BRPI0313651-5A priority patent/BR0313651A2/pt
Priority to US10/504,490 priority patent/US20050181042A1/en
Priority to DK03703650T priority patent/DK1474174T3/da
Priority to CA2475025A priority patent/CA2475025C/en
Priority to RU2004124042/15A priority patent/RU2302260C2/ru
Priority to SI200331606T priority patent/SI1474174T1/sl
Priority to ES03703650T priority patent/ES2324603T3/es
Priority to ZA200406399A priority patent/ZA200406399B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • General Preparation And Processing Of Foods (AREA)
SE0200475A 2002-02-15 2002-02-15 Oral farmaceutisk beredning SE0200475D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0200475A SE0200475D0 (sv) 2002-02-15 2002-02-15 Oral farmaceutisk beredning
ES03703650T ES2324603T3 (es) 2002-02-15 2003-02-14 Composicion para la administracion oral o rectal.
CNA038040131A CN101060862A (zh) 2002-02-15 2003-02-14 口服和直肠施用的组合物
KR10-2004-7012595A KR20040089633A (ko) 2002-02-15 2003-02-14 경구 또는 직장내 투여용 조성물
PCT/SE2003/000251 WO2003068267A1 (en) 2002-02-15 2003-02-14 Composition for oral or rectal administration
AT03703650T ATE430585T1 (de) 2002-02-15 2003-02-14 Zusammensetzung zur oralen oder rektalen verabreichung
PT03703650T PT1474174E (pt) 2002-02-15 2003-02-14 Composição para administração oral ou rectal
AU2003206355A AU2003206355B2 (en) 2002-02-15 2003-02-14 Composition for oral or rectal administration
EP03703650A EP1474174B1 (de) 2002-02-15 2003-02-14 Zusammensetzung zur oralen oder rektalen verabreichung
DE60327511T DE60327511D1 (de) 2002-02-15 2003-02-14 Zusammensetzung zur oralen oder rektalen verabreichung
MXPA04007946A MXPA04007946A (es) 2002-02-15 2003-02-14 Composicion para administracion oral o rectal.
JP2003567447A JP2005520816A (ja) 2002-02-15 2003-02-14 経口または直腸投与用組成物
NZ534812A NZ534812A (en) 2002-02-15 2003-02-14 Composition for oral or rectal administration based on lipid carrier materials
BRPI0313651-5A BR0313651A2 (pt) 2002-02-15 2003-02-14 composiÇço para administraÇço oral ou rectal
US10/504,490 US20050181042A1 (en) 2002-02-15 2003-02-14 Composition for oral or rectal administration
DK03703650T DK1474174T3 (da) 2002-02-15 2003-02-14 Præparat til oral eller rektal indgivelse
CA2475025A CA2475025C (en) 2002-02-15 2003-02-14 Solid composition for oral or rectal administration having a melting point of 25.degree.c or higher and comprising a mixture of polar glycolipids and non-polar lipids
RU2004124042/15A RU2302260C2 (ru) 2002-02-15 2003-02-14 Композиция для перорального или ректального введения
SI200331606T SI1474174T1 (sl) 2002-02-15 2003-02-14 Sestavek za oralno ali rektalno dajanje
ZA200406399A ZA200406399B (en) 2002-02-15 2004-08-12 Composition for oral or rectal administration.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200475A SE0200475D0 (sv) 2002-02-15 2002-02-15 Oral farmaceutisk beredning

Publications (1)

Publication Number Publication Date
SE0200475D0 true SE0200475D0 (sv) 2002-02-15

Family

ID=20286999

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200475A SE0200475D0 (sv) 2002-02-15 2002-02-15 Oral farmaceutisk beredning

Country Status (20)

Country Link
US (1) US20050181042A1 (de)
EP (1) EP1474174B1 (de)
JP (1) JP2005520816A (de)
KR (1) KR20040089633A (de)
CN (1) CN101060862A (de)
AT (1) ATE430585T1 (de)
AU (1) AU2003206355B2 (de)
BR (1) BR0313651A2 (de)
CA (1) CA2475025C (de)
DE (1) DE60327511D1 (de)
DK (1) DK1474174T3 (de)
ES (1) ES2324603T3 (de)
MX (1) MXPA04007946A (de)
NZ (1) NZ534812A (de)
PT (1) PT1474174E (de)
RU (1) RU2302260C2 (de)
SE (1) SE0200475D0 (de)
SI (1) SI1474174T1 (de)
WO (1) WO2003068267A1 (de)
ZA (1) ZA200406399B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201922D0 (sv) * 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Koagulationshindrande komposition (Anticoagulant Composition)
SE0400233D0 (sv) * 2004-02-04 2004-02-04 Ltp Lipid Technologies Provide Rektal komposition
EA012882B1 (ru) * 2005-04-28 2009-12-30 ДСМ АйПи ЭССЕТС Б.В. Фармацевтические лекарственные формы, содержащие липидную фазу
WO2007098446A2 (en) * 2006-02-21 2007-08-30 Accu-Break Pharmaceuticals, Inc. Method for minimizing variation in dosage forms
CN101278928B (zh) 2007-04-06 2011-09-07 常州高新技术产业开发区三维工业技术研究所有限公司 含左卡尼汀或其衍生物的药物组合物及其用途
CN101991557B (zh) * 2009-08-10 2013-09-18 杭州赛利药物研究所有限公司 一种盐酸万古霉素液体胶囊及其制备方法
WO2012144943A1 (en) * 2011-04-18 2012-10-26 Lipidor Ab Liquid carrier for oral delivery of a pharmacologically active agent
US10117885B2 (en) * 2011-08-11 2018-11-06 Allergy Research Group, Llc Chewable lipid supplements for treating pain and fibromyalgia
CN102631290A (zh) * 2012-04-05 2012-08-15 韩昌志 一种生产栓剂的综合法
US10456327B2 (en) 2015-08-28 2019-10-29 Craig Robertson Package for frozen nutrient pill

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7812466A (nl) * 1978-12-22 1980-06-24 Shell Int Research Werkwijze voor de bereiding van gasmengsels.
DE2951142C2 (de) * 1979-12-19 1983-11-03 A. Nattermann & Cie GmbH, 5000 Köln Suppositorium-Zubereitung von Indometacin oder Acemetacin
US4966776A (en) * 1983-04-11 1990-10-30 Board Of Regents, The University Of Texas System Compositions and methods of treating calcium renal stones
US4699776A (en) * 1985-06-28 1987-10-13 R. P. Scherer Corporation Suppositories containing analgesics, antipyretics or anti-inflammatory agents
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
SE9003100D0 (sv) * 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
EP0664701B1 (de) * 1992-10-16 1997-09-10 Glaxo Group Limited Geschmacksmaskierende zusammensetzungen von ranitidin
US5505982A (en) * 1994-01-28 1996-04-09 Fmc Corporation Chocolate confection
CA2182577C (en) * 1994-02-04 2002-08-20 Anders Carlsson Lipophilic carrier preparations
JP2948111B2 (ja) * 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物
DE29511421U1 (de) * 1995-07-14 1995-10-12 Chou, Wen San, An Ting, Tainan Luftkompressor
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
EP1022019A4 (de) * 1997-10-08 2006-07-19 Taisho Pharmaceutical Co Ltd Zäpfchenzusammensetzung
GB9724544D0 (en) * 1997-11-21 1998-01-21 Smithkline Beecham Plc Novel Formulation
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
SE9804192D0 (sv) * 1998-12-03 1998-12-03 Scotia Lipidteknik Ab New formulation
EP1043016B1 (de) * 1999-03-30 2014-08-20 Sodic Sa Pflanzenextrakt auf Glycerid-, Phospholipid- und Phytosphingolipidbasis, Verfahren für die Gewinnung dieses Extrakts und ihn enthaltende kosmetische Zusammensetzungen
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
JP4116436B2 (ja) * 2000-12-14 2008-07-09 エフ．ホフマン−ラ ロシュ アーゲー 自己乳化脂質マトリックス（ｓｅｌｍ）

Also Published As

Publication number Publication date
EP1474174A1 (de) 2004-11-10
DK1474174T3 (da) 2009-07-06
US20050181042A1 (en) 2005-08-18
AU2003206355A1 (en) 2003-09-04
NZ534812A (en) 2006-10-27
RU2302260C2 (ru) 2007-07-10
DE60327511D1 (de) 2009-06-18
ATE430585T1 (de) 2009-05-15
PT1474174E (pt) 2009-06-25
ES2324603T3 (es) 2009-08-11
BR0313651A2 (pt) 2008-11-11
ZA200406399B (en) 2005-09-12
CA2475025A1 (en) 2003-08-21
KR20040089633A (ko) 2004-10-21
EP1474174B1 (de) 2009-05-06
SI1474174T1 (sl) 2009-08-31
WO2003068267A1 (en) 2003-08-21
JP2005520816A (ja) 2005-07-14
CN101060862A (zh) 2007-10-24
RU2004124042A (ru) 2005-06-10
MXPA04007946A (es) 2005-06-08
CA2475025C (en) 2010-07-27
AU2003206355B2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
GB0022438D0 (en) Organic Compounds
BR0312427A (pt) Combinação, uso de uma combinação, método para a produção de um efeito inibitório de ibat em um animal de sangue quente, método de prevenção de diarréia, composição farmacêutica, método de tratamento de condições hiperlipidêmicas em um animal de sangue quente, e, uso de um sal metálico
NZ514574A (en) Novel method of treatment
GEP20053510B (en) Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
FIC20130042I1 (fi) Fampridiini tai sen suola tai solvaatti
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
IL158899A0 (en) Pharmaceutical compositions for inhibiting angiogenesis containing oleuropein and derivatives thereof
WO2005030753A3 (en) Therapeutic agents useful for treating pain
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
SE0200475D0 (sv) Oral farmaceutisk beredning
EP2142549A4 (de) Adenosinderivate, verfahren zu deren synthese und pharmazeutische zusammensetzungen zur prävention und behandlung von entzündlichen krankheiten, die diese als wirkstoff enthalten
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP1178796A4 (de) Aminoimidazolcarboxamidesalze zur vorbeugung und behandlung von leberkrankheiten
GR3032301T3 (en) N-hydroxyureas as antiinflammatory agents
MY140954A (en) Composition for oral or rectal administration
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
ATE369865T1 (de) Gerinnungshemmende zusammensetzung
MA28224A1 (fr) Nitro-oxyderives de medicaments contre l'hypertension.
SE0002354D0 (sv) New formulation
EP2101809A4 (de) Pharmazeutische zusammensetzung mit arazym zur prävention von leberfunktionsstörung
PL369845A1 (en) Use of 4-oxobutanoic acid derivatives in the treatment of inflammation